Lymphoma,%20T-Cell
Showing 1 - 25 of >10,000
Cutaneous T-cell Lymphoma Trial in Beijing (Linperlisib in combined with Chidamide)
Recruiting
- Cutaneous T-cell Lymphoma
- Linperlisib in combined with Chidamide
-
Beijing, Beijing, ChinaPeking Union Medical College Hospital
Sep 8, 2023
ASCT Versus Chemotherapy as First-Line Consolidation Therapy
Completed
- T-cell Lymphoma Adults
- consolidation with ASCT
- (no location specified)
Nov 25, 2023
Circulating Tumor DNA Sequencing in Peripheral T-cell Lymphomas
Not yet recruiting
- Peripheral T Cell Lymphoma
- circulating tumoral DNA detection
-
Rouen, FranceCentre Henri Becquerel
Oct 13, 2023
Extranodal NK T Cell Lymphoma, NK-Cell Leukemia Trial in Xuzhou (Anti-CD56 CAR T)
Recruiting
- Extranodal NK T Cell Lymphoma
- NK-Cell Leukemia
- Anti-CD56 CAR T
-
Xuzhou, Jiangsu, ChinaThe Affiliated Hospital of Xuzhou Medical University
Jul 10, 2023
Peripheral T-cell Lymphoma Trial (Linperlisib in combination with CHOP)
Not yet recruiting
- Peripheral T-cell Lymphoma
- Linperlisib in combination with CHOP
- (no location specified)
Jul 10, 2023
T-cell Lymphoma Patients After First-line Treatment Failure Trial (SHR2554; Chidamide analog tablets, SHR2554 analog tablets;
Not yet recruiting
- T-cell Lymphoma Patients After First-line Treatment Failure
- SHR2554; Chidamide analog tablets
- SHR2554 analog tablets; Chidamide
- (no location specified)
Nov 5, 2023
Peripheral T Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma, Refractory T-Cell Lymphoma Trial in Xiamen (Chidamide combined
Recruiting
- Peripheral T Cell Lymphoma
- +2 more
- Chidamide combined with Duvillisib
-
Xiamen, Fujian, ChinaThe First Affiliated Hosptial of Xiamen University
Nov 28, 2023
Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) Trial (GFH009)
Not yet recruiting
- Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
- (no location specified)
Jun 28, 2023
T Cell Lymphoma Trial in New Haven (Mogamulizumab, DA-EPOCH Protocol)
Not yet recruiting
- T Cell Lymphoma
- Mogamulizumab
- DA-EPOCH Protocol
-
New Haven, ConnecticutYale Smilow Cancer Hospital
Aug 14, 2023
nk/T-cell Lymphoma, Newly Diagnosed, Advanced Lymphoma Trial in Beijing (XPO1 inhibitor)
Recruiting
- nk/T-cell Lymphoma
- +2 more
- XPO1 inhibitor
-
Beijing, Haidian, ChinaChinaPLAGH
Apr 18, 2023
Newly Diagnosed Peripheral T-cell Lymphoma Trial in Wuhan (Duvelisib, Chidamide)
Recruiting
- Newly Diagnosed Peripheral T-cell Lymphoma
- Duvelisib, Chidamide
-
Wuhan, Hubei, ChinaUnion Hospital, Tongji Medical College, Huazhong University of S
Jul 27, 2023
Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma Trial in Changchun (Rituximab,
Recruiting
- Peripheral T-Cell Lymphoma, Not Otherwise Specified
- Angioimmunoblastic T-cell Lymphoma
- Rituximab
- +4 more
-
Changchun, Jilin, ChinaThe First Bethune Hospital of Jilin University
Apr 7, 2023
T-cell Lymphoma, CLL/SLL Trial in Birmingham (Tazemetostat, Acalabrutinib and Tazemetostat)
Not yet recruiting
- T-cell Lymphoma
- CLL/SLL
- Tazemetostat
- Acalabrutinib and Tazemetostat
-
Birmingham, AlabamaUniversity of Alabama at Birmingham
Aug 11, 2023
Remitoro in Recurrent or Refractory Peripheral T Cell Lymphoma
Recruiting
- Lymphoma, T-cell, Peripheral
- Lymphoma, T-cell, Cutaneous
-
Nagoya, Japan
- +2 more
Nov 24, 2022
Newly Diagnosed Peripheral T-cell Lymphoma Trial in Nanjing (CMOP+Chidamide)
Recruiting
- Newly Diagnosed Peripheral T-cell Lymphoma
-
Nanjing, Jiangsu, ChinaHematological Department, People's Hospital of Jiangsu Province
Jun 1, 2023
NK-T-Cell Lymphoma, Extranodal Trial in Shanghai (4 cycles of ESA regimen with sandwiched radiotherapy, 2 cycles of ESA regimen
Not yet recruiting
- NK-T-Cell Lymphoma, Extranodal
- 4 cycles of ESA regimen with sandwiched radiotherapy
- +2 more
-
Shanghai, Shanghai, ChinaRuijin Hospital
Sep 29, 2023
Cutaneous T Cell Lymphoma, Fungoides Mycosis Sezary Syndrome Trial in Ann Arbor (Pembrolizumab, Mogamulizumab)
Not yet recruiting
- Cutaneous T Cell Lymphoma
- Fungoides Mycosis Sezary Syndrome
-
Ann Arbor, MichiganUniversity of Michigan Comprehensive Cancer Center
Jul 13, 2023
Peripheral T Cell Lymphoma Trial in Beijing (Linperlisib in combined with Chidamide)
Recruiting
- Peripheral T Cell Lymphoma
- Linperlisib in combined with Chidamide
-
Beijing, Beijing/China, China
- +1 more
Oct 9, 2023
Cutaneous T-cell Lymphoma Retreated With Brentuximab Vedotin
Not yet recruiting
- T-Cell Lymphoma
- No intervention
-
Bordeaux, France
- +10 more
May 24, 2023
T Cell Lymphoma Trial (Cidapenem combined with azacitidine and mitoxantrone liposome (CAM) regimen)
Not yet recruiting
- T Cell Lymphoma
- Cidapenem combined with azacitidine and mitoxantrone liposome (CAM) regimen
- (no location specified)
Mar 6, 2023
Extranodal NK/T-cell Lymphoma Trial (Sugemalimab, Placebo, Pegaspargase)
Not yet recruiting
- Extranodal NK/T-cell Lymphoma
- Sugemalimab
- +4 more
- (no location specified)
Jan 17, 2023
Peripheral T Cell Lymphoma Trial (CHOP+selinexor+5-Azacitidine, CHOP+duvelisib+5-Azacitidine, CHOP+chidamide+tislelizumab)
Not yet recruiting
- Peripheral T Cell Lymphoma
- CHOP+selinexor+5-Azacitidine
- +2 more
- (no location specified)
Dec 29, 2022
NK-T-Cell Lymphoma, Extranodal Trial (Pegaspargase Combined With Gemcitabine, Etoposide, Liposomal Mitoxantrone Hydrochloride
Not yet recruiting
- NK-T-Cell Lymphoma, Extranodal
- Pegaspargase Combined With Gemcitabine, Etoposide, Liposomal Mitoxantrone Hydrochloride and Dexamethasone (P-GEMD) regimen
- (no location specified)
Mar 7, 2023
NK/T-cell Lymphoma Trial in Shanghai (Positron Emission Tomography/Magnetic Resonance (PET/MR))
Not yet recruiting
- NK/T-cell Lymphoma
- Positron Emission Tomography/Magnetic Resonance (PET/MR)
-
Shanghai, Shanghai, ChinaRuijin Hospital
Dec 14, 2022